SCHEMBL975796

SCHEMBL975796

CC(ON1C(C)(C)CC(OCc2ccccc2)(OCc2ccccc2)CC1(C)C)c1ccc(OCC2CO2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GRM2 Q14416 1/20 0.37
TP53 P04637 4/20 0.36
ALDH1A1 P00352 4/20 0.36
TSHR P16473 3/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 2/20 0.36
HIF1A Q16665 2/20 0.36
CYP1A2 P05177 1/20 0.36
PPARG P37231 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
PKM P14618 2/20 0.34
CYP3A4 P08684 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
FGFR1 P11362 1/20 0.34
SRC P12931 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL975101 0.93 TDP1 (0.38) TDP1MEN1KMT2AGRM2TP53
SCHEMBL975968 0.87 ALDH1A1 (0.40) TDP1MEN1KMT2AGRM2TP53
SCHEMBL977007 0.86 ALDH1A1 (0.39) TDP1MEN1KMT2AGRM2TP53
SCHEMBL976463 0.85 TP53 (0.38) TDP1MEN1KMT2AGRM2TP53
SCHEMBL976657 0.84 ALDH1A1 (0.41) TDP1MEN1KMT2AGRM2TP53
SCHEMBL974312 0.84 ALDH1A1 (0.38) TDP1MEN1KMT2AGRM2TP53
SCHEMBL974710 0.83 ALDH1A1 (0.37) TDP1MEN1KMT2AGRM2TP53
SCHEMBL13715732 0.83 OPRM1 (0.39) MEN1KMT2AALDH1A1TSHRCYP1A2
SCHEMBL978061 0.83 TDP1 (0.37) TDP1MEN1KMT2AGRM2TP53
SCHEMBL976335 0.82 TDP1 (0.37) TDP1MEN1KMT2AGRM2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173570-A1 N-alkoxy-4, 4-dioxy-polyalkyl-piperidine compounds, with glycidyl or alkylcarbonyl groups as functional initiators for controlled radical polymerization FUSO FRANCESCO 2007-07-26 US claimed
EP-1341763-B1 N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, WITH GLYCIDYL OR ALKYLCARBONYL GROUPS AS FUNCTIONAL INITIATORS FOR CONTROLLED RADICAL POLYMERIZATION CIBA SC HOLDING AG (CH) 2004-06-16 EP claimed
EP-1341763-A2 N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, WITH GLYCIDYL OR ALKYLCARBONYL GROUPS AS FUNCTIONAL INITIATORS FOR CONTROLLED RADICAL POLYMERIZATION Ciba SC Holding AG (CH) 2003-09-10 EP claimed
WO-2002048109-A2 N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINES AS RADICAL POLYMERIZATION INITIATORS CIBA SPECIALTY CHEMICLAS HOLDING INC. (CH) 2002-06-20 WO claimed
US-7868171-B2 N-alkoxy-4, 4-dioxy-polyalkyl-piperidines as radical polymerization initiators CIBA SPECIALTY CHEMICALS CORP. (US) 2011-01-11 US disclosed
US-7868171-B2 N-alkoxy-4, 4-dioxy-polyalkyl-piperidines as radical polymerization initiators CIBA SPECIALTY CHEMICALS CORP. (US) 2011-01-11 US disclosed
US-7868171-B2 N-alkoxy-4, 4-dioxy-polyalkyl-piperidines as radical polymerization initiators CIBA SPECIALTY CHEMICALS CORP. (US) 2011-01-11 US disclosed
US-20070173570-A1 N-alkoxy-4, 4-dioxy-polyalkyl-piperidine compounds, with glycidyl or alkylcarbonyl groups as functional initiators for controlled radical polymerization FUSO FRANCESCO 2007-07-26 US disclosed
US-20070173570-A1 N-alkoxy-4, 4-dioxy-polyalkyl-piperidine compounds, with glycidyl or alkylcarbonyl groups as functional initiators for controlled radical polymerization FUSO FRANCESCO 2007-07-26 US disclosed
US-20070173570-A1 N-alkoxy-4, 4-dioxy-polyalkyl-piperidine compounds, with glycidyl or alkylcarbonyl groups as functional initiators for controlled radical polymerization FUSO FRANCESCO 2007-07-26 US disclosed
US-7235663-B2 N-alkoxy-4,4-dioxy-polyalkyl-piperidines as radical polymerization inhibitors CIBA SPECIALTY CHEMICALS CORP. (US) 2007-06-26 US disclosed
US-7235663-B2 N-alkoxy-4,4-dioxy-polyalkyl-piperidines as radical polymerization inhibitors CIBA SPECIALTY CHEMICALS CORP. (US) 2007-06-26 US disclosed
US-7235663-B2 N-alkoxy-4,4-dioxy-polyalkyl-piperidines as radical polymerization inhibitors CIBA SPECIALTY CHEMICALS CORP. (US) 2007-06-26 US disclosed
US-7144691-B2 Color photographic recording material CIBA SPECIALTY CHEMICALS CORPORATION (US) 2006-12-05 US disclosed
US-20050079455-A1 Colour photographic recording material CIBA SPECIALTY CHEMICALS CORP. 2005-04-14 US disclosed
EP-1493057-A1 COLOUR PHOTOGRAPHIC RECORDING MATERIAL Ciba SC Holding AG (CH) 2005-01-05 EP disclosed
EP-1341763-B1 N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, WITH GLYCIDYL OR ALKYLCARBONYL GROUPS AS FUNCTIONAL INITIATORS FOR CONTROLLED RADICAL POLYMERIZATION CIBA SC HOLDING AG (CH) 2004-06-16 EP disclosed
WO-2003075091-A1 COLOUR PHOTOGRAPHIC RECORDING MATERIAL CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-09-12 WO disclosed
EP-1341763-A2 N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, WITH GLYCIDYL OR ALKYLCARBONYL GROUPS AS FUNCTIONAL INITIATORS FOR CONTROLLED RADICAL POLYMERIZATION Ciba SC Holding AG (CH) 2003-09-10 EP disclosed
WO-2002048109-A2 N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINES AS RADICAL POLYMERIZATION INITIATORS CIBA SPECIALTY CHEMICLAS HOLDING INC. (CH) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173570-A1 N-alkoxy-4, 4-dioxy-polyalkyl-piperidine compounds, with glycidyl or alkylcarbonyl groups as functional initiators for controlled radical polymerization PTGER4, ALKBH3, PIGO TDP1 3387/4885MEN1 4792/4885KMT2A 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.